MGRM:NSD-Monogram Orthopaedics Inc. Common Stock (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 2.86

Change

+0.16 (+5.93)%

Market Cap

USD 0.11B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Monogram Technologies Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+3.92 (+5.86%)

USD 23.46B
PODD Insulet Corporation

+12.89 (+5.23%)

USD 17.22B
MASI Masimo Corporation

+4.70 (+2.98%)

USD 7.80B
BRKR Bruker Corporation

+1.08 (+2.85%)

USD 5.53B
IRTC iRhythm Technologies Inc

+2.14 (+2.08%)

USD 3.28B
PRCT Procept Biorobotics Corp

-3.14 (-5.64%)

USD 2.85B
TMDX TransMedics Group Inc

+1.93 (+2.09%)

USD 2.73B
QDEL Quidel Corporation

+2.05 (+7.97%)

USD 2.42B
LIVN LivaNova PLC

+0.93 (+2.56%)

USD 1.95B
NVCR Novocure Ltd

+0.78 (+4.39%)

USD 1.81B

ETFs Containing MGRM

SHLD Global X Funds 6.35 % 0.00 %

+0.95 (+1.93%)

USD 1.31B
CIBR First Trust NASDAQ Cybers.. 6.02 % 0.00 %

+2.01 (+1.93%)

USD 8.00B
EEA:PA BNP Paribas Easy FTSE EPR.. 4.00 % 0.00 %

+0.06 (+1.93%)

USD 0.07B
EEE:PA BNP Paribas Easy FTSE EPR.. 4.00 % 0.00 %

+0.05 (+1.93%)

USD 0.14B
EEAA:XETRA BNP Paribas Easy FTSE EPR.. 4.00 % 0.00 %

+0.07 (+1.93%)

USD 0.20B
IPRP:SW iShares European Property.. 2.74 % 0.00 %

+0.22 (+1.93%)

USD 0.97B
EMIF iShares Emerging Markets .. 0.00 % 0.75 %

+0.33 (+1.93%)

USD 8.65M
UAE iShares MSCI UAE ETF 0.00 % 0.59 %

+0.34 (+1.93%)

USD 0.10B
EEAA:F BNP Paribas Easy - FTSE E.. 0.00 % 0.00 %

-0.05 (1.93%)

N/A
IM2A:F BNP Paribas Easy - FTSE E.. 0.00 % 0.00 %

-0.04 (1.93%)

N/A
IM2A:XETRA BNP Paribas Easy - FTSE E.. 0.00 % 0.00 %

+0.06 (+1.93%)

N/A
IQQP:XETRA iShares European Property.. 0.00 % 0.00 %

+0.27 (+1.93%)

N/A
IPRE:XETRA iShares European Property.. 0.00 % 0.00 %

+0.03 (+1.93%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.68% 89% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.68% 89% A- 90% A-
Trailing 12 Months  
Capital Gain 21.19% 82% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.19% 82% B 79% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -11.13% 31% F 22% F
Dividend Return -11.13% 31% F 21% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.63% 95% A 75% C
Risk Adjusted Return -53.93% 20% F 14% F
Market Capitalization 0.11B 50% F 42% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector